BS, Fordham University; MS, Ph.D., University of Connecticut
Maureen Ferran earned her M.S. and Ph.D. in Genetics from the University of Connecticut, where she studied how viruses evade the host innate immune response. She then went to the Laboratory of Viral Genetics within the National Institute of Allergy and Infectious Disease at the National Institutes of Health, where she studied human papillomavirus.
She is now an associate professor in the Thomas H. Gosnell School of Life Sciences at the Rochester Institute of Technology in Rochester NY where she teaches courses including Virology, Infectious Disease: Impact on Society and Culture, and Eukaryotic Gene Regulation and Disease.
Her research lab focuses on the development of viruses as a cancer therapy and as a molecular tool to understand innate immunity and age-related diseases. Studies in her lab also investigate the use of imaging agents to detect and target breast cancer.
In the News
August 4, 2022
Monkeypox vaccines: A virologist answers 6 questions about how they work, who can get them and how well they prevent infection
The Conversation asks Maureen Ferran, associate professor in the Thomas H. Gosnell School of Life Sciences, about the two vaccines that can protect against monkeypox.
March 28, 2022
RIT scientist receives NIH grant to study viruses with potential to treat prostate cancer
The National Institutes of Health are funding RIT scientists to explore vesicular stomatitis virus’s (VSV) potential for treating prostate cancer. Associate Professor Maureen Ferran from the Thomas H. Gosnell School of Life Sciences secured a three-year, $451,718 Research Enhancement Award (R15) grant from the NIH to investigate prostate cancer cells’ susceptibility to the virus.
January 19, 2022
CORBEVAX, a new patent-free COVID-19 vaccine, could be a pandemic game changer globally
Essay by Maureen Ferran, associate professor in the Thomas H. Gosnell School of Life Sciences, published by The Conversation.
April 28, 2022
School of Life Sciences team publishes paper in ‘Biophysical Reports’
April 14, 2022
RIT study on prostate cancer treatment underway with $450,000 fund
March 4, 2022
Schmitthenner, Ferran, and Sweet win grant
January 31, 2022
Omicron: Subvariant BA.2 & CORBEVAX